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Abstract
Objectives We aimed to develop logistic regression (LR)
models for classifying prostate cancer within the transition zone
on multi-parametric magnetic resonance imaging (mp-MRI).
Methods One hundred and fifty-five patients (training cohort,
70 patients; temporal validation cohort, 85 patients)
underwent mp-MRI and transperineal-template-prostate-map-
ping (TPM) biopsy. Positive cores were classified by cancer
definitions: (1) any-cancer; (2) definition-1 [≥Gleason 4+3
or≥6 mm cancer core length (CCL)] [high risk significant];
and (3) definition-2 (≥Gleason 3+4 or≥4 mm CCL) cancer
[intermediate–high risk significant]. For each, logistic-
regression mp-MRI models were derived from the training
cohort and validated internally and with the temporal cohort.
Sensitivity/specificity and the area under the receiver operat-
ing characteristic (ROC-AUC) curve were calculated. LR
model performance was compared to radiologists’
performance.
Results Twenty-eight of 70 patients from the training cohort,
and 25/85 patients from the temporal validation cohort had
significant cancer on TPM. The ROC-AUC of the LR model
for classification of cancer was 0.73/0.67 at internal/temporal
validation. The radiologist A/B ROC-AUC was 0.65/0.74
(temporal cohort). For patients scored by radiologists as Pros-
tate Imaging Reporting and Data System (Pi-RADS) score 3,
sensitivity/specificity of radiologist A ‘best guess’ and LR
model was 0.14/0.54 and 0.71/0.61, respectively; and radiol-
ogist B ‘best guess’ and LR model was 0.40/0.34 and 0.50/
0.76, respectively.
Conclusions LR models can improve classification of Pi-
RADS score 3 lesions similar to experienced radiologists.
Key Points
• MRI helps find prostate cancer in the anterior of the gland
• Logistic regression models based on mp-MRI can classify
prostate cancer
• Computers can help confirm cancer in areas doctors are
uncertain about
Keywords Magnetic resonance imaging . Prostatic
neoplasms . Diagnosis, computer assisted . Logistic models
Abbreviations
PSA Prostate specific antigen
TRUS Transrectal ultrasound guided biopsy
CAD Computer assisted diagnosis
LR Logistic regression
TPM Template mapping biopsy
DWI Diffusion weighted imaging
ADC Apparent diffusion coefficient
DCE Dynamic contrast enhanced
mp Multi-parametric
SI Signal intensity
T2-nSI Normalized T2 signal intensity
DCE-nSI Early contrast enhanced T1 signal intensity
Nikolaos Dikaios and Shonit Punwani are contributed equally towards
the manuscript
N. Dikaios : J. Alkalbani :H. S. Sidhu : T. Fujiwara : S. Halligan :
S. Taylor :D. Atkinson : S. Punwani (*)
Centre for Medical Imaging, University College London, 3rd Floor
East Wing, 250 Euston Road, London, UK NW1 2PG
e-mail: shonit.punwani@gmail.com
N. Dikaios :A. Kirkham :C. Allen : S. Halligan : S. Taylor :
D. Atkinson : S. Punwani
Departments of Radiology, University College London Hospital, 235
Euston Road, London, UK NW1 2BU
M. Abd-Alazeez :H. Ahmed :M. Emberton
Research Department of Urology, University College London,
London, UK NW1 2PG
A. Freeman
Department of Histopathology, University College London Hospital,
London, UK NW1 2PG
Eur Radiol (2015) 25:523–532
DOI 10.1007/s00330-014-3386-4
SoE Slope of enhancement
ME Maximum enhancement
Etype Curve type
AUCtot Total area under the dynamic contrast
enhanced signal intensity time curve
ROC Receiver operator characteristic
ROI Region of interest
AUC Area under curve
Introduction
Increasing recognition of anteriorly located prostate cancers
has resulted from the gradual transition of a diagnostic path-
way reliant primarily on prostate specific antigen (PSA) and
transrectal ultrasound (TRUS) guided biopsy—a strategy that
selectively identifies peripheral zone cancers—to one that
incorporates imaging, notably multi-parametric magnetic res-
onance imaging (mp-MRI) [1, 2].
Although mp-MRI facilitates identification of more anteri-
or cancers, its overall diagnostic accuracy is likely lower in
this part of the prostate compared to the posteriorly located
peripheral zone [3, 4]. The reason for this relates to benign
hyperplasia nodules. Against the heterogeneous signal of an
expanded transition zone, tumours are much more difficult to
differentiate [5]. In other cancer types (colorectal [6], lung [7]
and breast [8]), discriminating tumours has been in part aided
by computer-assisted diagnosis (CAD). This term refers to
software that prompts observers towards potential abnormal-
ities. However, most developed prostate CAD relies upon the
evaluation of a single MRI parameter informed by data exclu-
sively from the peripheral zone [3, 9–12]. It is possible that
when applied to the transition zone, the accuracy of these
diagnostic models is compromised as a result [13, 14]. Indeed,
recent work suggests that a multi-parametric CADmodel may
provide improved results [15].
Our aim is to derive and validate logistic regression
(diagnostic) models for classifying transition zone prostate
cancer on multi-parametric MRI (mp-MRI).
Material and methods
Our local institutional review board approved the study and
waived the requirement for individual consent for retrospec-
tive analysis of patient data collected as part of clinical trials/
routine care (R&D No: 12/0195 date: 16 July 2012).
Patient cohort
The cohort comprised men with clinically suspected prostate
cancer (elevated PSA ± abnormal digital rectal examination ±
family history of prostate cancer, etc.) undergoing prostatic
mp-MRI prior to template-prostate-mapping (TPM) biopsies.
Two temporally separated patient cohorts were identified:
February 2007 to September 2010 (training cohort) and Oc-
tober 2010 to January 2013 (temporal validation cohort).
Patients were identified from a total of 509 TPM clinical
records.Menwho hadundergoneTPMbiopsywithin 6months
prior to mp-MRI, or previous treatment for prostate cancer,
were excluded to avoid biopsy-associatedMRI signal changes.
Men with incomplete mp-MRI data sets were also excluded.
In total, 155 men were eligible. Seventy men (mean age
61 years, range 42–78) with a mean PSA of 8.39 ng/ml (range
1.2–40 ng/ml) and mean prostate gland volume of 44.1 ml
(range 18.9–101 ml) comprised the training cohort. Eighty-
five men (mean age 63 years, range 45–77) with a mean PSA
of 8.66 ng/ml (range 0.2–39 ng/ml) and mean prostate gland
volume of 44.1 ml (range 20–133 ml) comprised the temporal
validation cohort.
Multi-parametric magnetic resonance imaging
Subjects underwent mp-MRI using a 1.5 T static magnet
(Avanto, Siemens, Erlangen, Germany) and pelvic-phased
array coil; 0.2 mg/kg (maximum 20 mg) of spasmolytic
(Buscopan; Boehringer Ingelheim, Ingelheim, Germany)
was administered intravenously to reduce peristalsis. The
mp-MRI included axial and coronal small field of view T2-
weighted imaging; and was supplemented by axial diffusion
weighted imaging (DWI) and dynamic contrast enhanced
(DCE) imaging (Table 1).
Transperineal template-prostate-mapping biopsy
TPM was conducted following mp-MRI over a median time
of 127 days (range 17–332 days) for the training cohort, and
over a mean time of 75 days (range 13–384 days) for the
temporal validation cohort. The biopsy was performed as
previously reported [16, 17]. Briefly, systematic biopsy of
the whole gland was conducted through a brachytherapy
template-grid and 5 mm sampling frame, conforming to a
sampling density of approximately 1 core/cc of tissue uni-
formly over the prostate. Biopsies were grouped and potted
into 20 zones, modified from a technique reported by Barzell
et al. [18]; each zone, with the exception of the lateral zone,
had both apical and basal samples.
Histopathology review
Three differing definitions of cancer significance were used
for the study, reflecting the lack of current consensus regard-
ing clinically important disease (i.e., disease that warrants
treatment and therefore detection). The first was ‘any-cancer’,
with the second and third definitions using different thresholds
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for significant cancer based on widely used volume assess-
ments (0.5 ml and 0.2 ml), combined with dominant/non-
dominant Gleason grade 4. TPM cancer core length (CCL)
values that best predict volumes were used to infer volume as
described previously, where a TPM CCL of≥4 mm signifies a
tumour volume of≥0.2 ml and a TPM CCL of≥6 mm sig-
nifies a tumour volume of≥0.5 ml [19]. For clinically signif-
icant disease; definition-1 [high-risk] cancer was defined as≥
Gleason 4+3 or ≥6 mm CCL; and definition-2 [intermediate
and high-risk] as ≥ Gleason 3+4 or≥4 mm CCL.
For each patient, the modified Barzell zones were grouped
into four anterior sectors (Fig. 1). Histopathology from the
posterior and lateral Barzell zones was disregarded, as this
predominantly represented the peripheral zone. Anterior sec-
tors were classified as either positive or negative for each of
the three cancer definitions of any-cancer, definition-1 cancer
and definition-2 cancer [19].
Training cohort review
Images were viewed using Osirix (version. 3.5.1; Geneva,
Switzerland). Two radiologists with 5 and 7 years of mp-
MRI experience (300–400 mp-MRI prostate scans/year each)
reviewed each image in consensus, while being aware of
pathological status of each patient and having access to histo-
pathology reports.
Observers visually matched mp-MRI findings with the
histological reference. For the purposes of the study, assess-
ment was limited to the transition zone left/right apical and
basal sectors only. Apical/basal sectors were split at half the
cranio-caudal height of the prostate; anterior/posterior sectors
at the level of the urethra; right/left sides by the midline; and
lateral sectors were defined as extending 2 cm from the
midline or in smaller glands up to the medial highest extent
of the anterior horn of the peripheral zone.
T2-weighted, DWI and DCE images were reviewed simul-
taneously, and the transition zone focus most suspicious for
disease (as confirmed on the histopathology report) was iden-
tified as per Prostate Imaging Reporting and Data System (Pi-
RADS) criteria [20] and contoured. Where no transition zone
tumour was identified on mp-MRI despite positive histopa-
thology, a 1-cm2 region of interest (ROI) was located within
the sector pathologically reported as containing the most
significant tumour definition. Where no tumour was present
Table 1 Multi-parametric MRI sequence parameters
T2w TSE
axial / coronal
EPI-DWI T1 3D
FLASH*
Repetition time (ms) 5170 / 5240 2100 5.61
Echo time (ms) 92 / 104 98 2.5
Flip angle (degrees) 180 / 150 90 15
Echo train length 22 / 24 172 n/a
Bandwidth (Hz/Px) 190 / 190 968 300
Field of view (mm) 180 / 180 260 260
Phase FoV % 100 / 100 100 100
Slice thickness (mm) 3 / 3 5 3
Slice gap (mm) 0.3 / 0.3 0 0.6
Averages 2 / 2 16 1
Phase encoding
direction
A>P / R>L A>P A>P
Fat saturation No / No Yes Yes
Base matrix 256 / 256 172 192
Matrix phase % 95 / 95 100 100
b-values (s.mm-2) n/a 0, 300, 500, 1000 n/a
No. of acquisitions 1 / 1 1 35
Temporal resolution
(seconds)
n/a n/a 16
Total acquisition
time (mins)
3 m 54 s / 4 m 18 s 3 m 39 s 10 m
*dynamic contrast enhanced MRI – 0.2 ml/kg intravenous gadolinium
contrast agent injected at the beginning of acquisition 6 at 3 ml/s followed
by a saline flush of 20 ml
T2w TSE – T2 weighted turbo spin echo; EPI-DWI – Echo planar
imaging - diffusion weighted imaging; FLASH – Fast low angle shot
Fig. 1 Standard modified Barzell zone schematic used for reporting of
template biopsy results. Green disease (any-cancer definition) defined as
≤ Gleason 3+3 and a cancer core length of <4 mm; yellow disease
(definition-2 cancer definition) as ≥ Gleason 3+4 or a cancer core length
of≥4 mm but<6 mm; and red (definition-1 cancer definition) as ≥
Gleason 4+3 or a cancer core length of≥6 mm. Barzell zones 9 (right-
medial-anterior-apical) and 3 (right-parasagittal-anterior-apical) were
grouped into a right anterior apical; 7 (left-medial-anterior-apical) and
1 (left-parasagittal-anterior-apical) into left anterior apical; 10 (right-
medial-anterior-basal) and 4 (right-parasagittal-anterior-basal) into right
anterior basal; and 8 (left-medial-anterior-basal) and 2 (left-parasagittal-
anterior-basal) into left anterior basal quadrants
Eur Radiol (2015) 25:523–532 525
within anterior sectors on histopathology, a 1-cm2 ROI was
located within any one of the four sectors to encompass a
representative area of non-malignant tissue.
Consequently, a single ROI confined to an individual sec-
tor was contoured within the transition zone for each patient
and a record was made of the positive/negative status of the
ROI for each cancer definition.
Calculation of mp-MRI quantitative parameters of the training
cohort
The mean signal intensity (SI) of the ROI on T2-weighted,
early arterial contrast enhanced images and corresponding
apparent diffusion coefficient (ADC) images were recorded
for each patient. Additionally, the mean SI of the obturator
internus muscle was measured on T2-weighted and early
arterial contrast-enhanced images for normalization of T2
and contrast-enhanced transition zone SIs between patients.
Normalized T2 (T2-nSI) and early contrast enhanced T1 SI
(DCE-nSI) were derived by taking the ratio of prostate/muscle
ROI SI. Quantitative parameters were derived from the DCE
MRI signal enhancement time curve. Initial slope of enhance-
ment (SoE), maximum enhancement (ME), curve type
(Etype), and total area under the time-intensity curve
(AUCtot) were defined as previously reported [21]. Briefly,
ME was defined as (peak enhancement SI – baseline SI)/
baseline SI; and SoE as the gradient of the SI time curve
between the last point of baseline SI and the inflexion point
following initial rapid enhancement. Finally, Etype was cate-
gorized as type 1 if the SI increased with no subsequent
decrease or levelling (threshold as late enhancement>10 %
of ME); and type 3 if SI increased rapidly and then decreased
after a peak (threshold as late enhancement<10 % of ME);
and type 2 when the SI levelled following maximum enhance-
ment (threshold as late enhancement within ±10 % of ME).
DCE analysis based on the extended Toft pharmacokinetic
[22] model was also performed, deriving blood plasma vol-
ume vp; transfer rates Ktrans, kep between plasma and extracel-
lular extravascular space.
Development of LR models
Individual logistic regression models were derived for each of
the three cancer definitions from the training cohort. The score
test was used to select the mp-MRI parameters most likely to
contribute significantly (p<0.05) for inclusion in each model
[23].
Logistic regression was preferred over linear discriminant
analysis (LDA), because it does not require the independent
variables to be normally distributed, linearly related, nor of
equal variance within each group [24]. Moreover, similar to
LDA, logistic regression provides a deterministic model yield-
ing weighting factors for each contributing variable, easing
interpretation and clinical application of results compared
with neural network models (which can also more easily
over-fit the data).
Validation of LR models
Data were analysed with the Statistical Package for Social
Sciences, version 19.0 (SPPS Inc., Chicago, IL, USA).
Internal validation of each of the three LR models was
performed separately using the training cohort (n=70). The
receiver operator characteristic area under the curve (ROC
AUC) was calculated for each model prior to and following
leave-one-out analysis [25]. For leave-one-out analysis, one
patient’s data was excluded, and a model was generated from
the remaining patients. The model was then tested on the
excluded data to calculate a predictive probability. The pro-
cess was repeated for all patients to calculate 70 predictive
probabilities. An ROC curve was then constructed from the
predictive probabilities. Temporal validation of the LR model
was then performed by its application to the temporal valida-
tion cohort (n=85).
Performance of a single parameter T2 alone LR model was
assessed against the multi-parametric LRmodel for prediction
of definition-2 cancer using ROC analysis.
Comparison of LR models against radiologists’ performance
in the temporal validation cohort
Two radiologists (A and B) unaware of the histopathology
independently reviewed and contoured suspected transition
zone lesions on temporal cohort mp-MRI examinations.
Where no suspect lesion was identified, the radiologists
placed a 1-cm ROI in any of the four transition zone sectors.
The sector containing each ROI was recorded.
The radiologists scored all ROIs for the presence/absence
of significant (a minimum of definition-2 [17]) cancer using a
1 to 5 scale (1=highly likely benign, 2=likely benign, 3=
equivocal, 4=likely significant cancer, 5=highly likely signif-
icant cancer) as per Pi-RADS mp-MRI scoring criteria [20].
Figures 2, 3 and 4 demonstrate radiologists’ Pi-RADS scores
of 2, 3 and 5 respectively.Whenever a score of 3 was ascribed,
the radiologists further dichotomized the score to a 3+ or a 3-
based on the ‘best guess’ of whether significant cancer was
more or less likely than 50 %.
The sector containing the radiologists’ scored ROI was
then matched against histopathology and classified as
positive/negative for each of the three cancer definitions.
Separate ROC curves were derived and sensitivity/
specificity analysis was performed using Pi-RADS scores
of≥3 and a≥4 threshold score as positive for significant
cancer on mp-MRI.
Quantitative parameters derived from ROIs were (as de-
scribed for the training cohort) used to test the LR models.
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ROC and sensitivity/specificity analysis at a probability
threshold of>0.5 was performed.
Results
For the training cohort, 37 of the 70 (53 %) localized ROIs
were classified by histopathology as positive for any-cancer;
28 (40 %) of these reached the threshold for definition-2, and
25 (36 %) reached definition-1 cancer. For the temporal val-
idation patient cohort, 46 of the 85 (54 %) localized ROIs
were classified by histopathology as positive for any-cancer;
25 (29 %) of these reached the threshold for definition-2, and
14 (16 %) reached definition-1 cancer. The median tumour
volume of histologically confirmed definition-2 and definition
1 lesions scored as Pi-RADS scores 3 to 5, and was localizable
on mp-MRI at 0.8 ml (range, 0.2–1.2 ml).
Derivation of LR models
The score test confirmed that T2-nSI, ADC, and ME were
most contributory to ROI classification for all cancer defini-
tions (Table 2). The logistic regression equations for the
diagnostic multi-parametric model for any-cancer, definition-
2 and definition-1 cancer (Eqs. 1–3) are given below:
Any-cancer:
In Oddsð Þ ¼ 5:952 − 1:343 ⋅ ADC − 0:227 ⋅ T2nSI − 2:379 ⋅ME ð1Þ
Definition-2 cancer:
In Oddsð Þ ¼ 5:347þ 0:332 ⋅ ADC − 0:974 ⋅ T2nSI − 1:730 ⋅ME ð2Þ
Definition-1 cancer:
In Oddsð Þ ¼ 4:844þ 0:194⋅ADC − 0:895⋅T2nSI−1:659⋅ME ð3Þ
Fig. 2 Axial multi-parametric
MR images [(a) T2 weighted, (b)
Apparent diffusion coefficient
map, (c) pre-contrast T1, and (d)
early post contrast T1] of a right
anterior basal region (yellow
arrows) Pi-RADS score 2/5.
Template mapping biopsy
revealed benign change only
within the corresponding Barzell
zones (10 and 4)
Fig. 3 Axial multi-parametric
MR images [(a) T2 weighted, (b)
Apparent diffusion coefficient
map, (c) pre-contrast T1, and (d)
early post contrast T1] of a left
anterior apical region (yellow
arrows) Pi-RADS score 3/5.
Template mapping biopsy
revealed definition one tumour
within the corresponding Barzell
zones (1 and 7)
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Validation of LR model performance
The ROC-AUC of the diagnostic model for a positive diag-
nosis for any-cancer, definition-2 cancer and definition-1 can-
cer was 0.78 (95 % CI 0.67–0.89), 0.8 (95 % CI 0.70–0.90),
and 0.79 (95 % CI 0.69–0.89), respectively, prior to leave-
one-out analysis; and 0.73 (95 % CI 0.61–0.85), 0.73 (95 %
CI 0.61–0.85), and 0.71 (95 % CI 0.58–0.84), respectively,
following leave-one-out analysis.
The ROC curve for each diagnostic model applied to the
temporal validation patient group is given in Fig. 5a. The
ROC-AUC for the any-cancer, definition-2 and definition-1
cancer model was 0.76 (95 % CI 0.66–0.87), 0.67 (95 % CI
0.55–0.79) and 0.70 (95 % CI 0.55–0.85). For the T2 alone
LR model, the ROC-AUC was 0.62 (95 % CI 0.50–0.76),
suggesting little additional benefit of mp-MRI.
Applying a probability threshold of>0.5 as positive for
cancer, the sensitivity/specificity of LR for any-cancer,
definition-2 and definition-1 was 0.91/0.26; 0.60/0.73; 0.71/
0.70; respectively.
Specifically for equivocally (Pi-RADS 3; 20/85 for radiol-
ogist A, 39/85 for radiologist B) scored MRI lesions within
the temporal validation group: for radiologist A, the mp-MRI
LRmodel had an ROC-AUC of 0.65 (95%CI 0.40–0.89) and
the T2 alone LR model had an ROC-AUC of 0.49 (95 % CI
0.24-0.75), suggesting additional benefit of mp-MRI in this
patient subset. For radiologist B, the mp-MRI LR model had
an ROC-AUC of 0.59 (95 % CI 0.39–0.79) and the T2 LR
model had an ROC-AUC of 0.50 (95 % CI 0.28–0.71), again
suggesting additional benefits of an mp-MRI model. The
sensitivity/ specificity of the definition-2 mp-MRI LR model
was 0.71/0.61 for radiologist A and 0.50/076 for radiologist B
for the Pi-RADS 3 group.
Comparison with radiologist performance
The radiologists’ Pi-RADS score for the temporal validation
patient cohort are given in Table 3.
Figure 5b illustrates the ROC curve of overall performance
of radiologists A and B (and comparative LR model) for
prediction of clinically significant (definition-2) cancer for
the temporal validation group.
The ROC-AUC for radiologist Awas 0.65 (95 % CI 0.51–
0.79). The sensitivity/specificity of radiologist A for cancer
was 0.45/1.0, 0.52/0.94 and 0.64/0.93 using a score≥3 as
positive; and 0.20/1.0, 0.24/0.95 and 0.35/0.94 using≥4 as
positive for any-cancer, definition-2 and definition-1 cancer,
respectively.
Fig. 4 Axial multi-parametric
MR images [(a) T2 weighted, (b)
Apparent diffusion coefficient
map, (c) pre-contrast T1, and (d)
early post contrast T1] of a right
anterior basal region (yellow
arrows) Pi-RADS score 5/5.
Template biopsies revealed
definition one tumour within the
corresponding Barzell zones (10
and 4)
Table 2 Score test results for quantitative mp-MRI parameters
MR
Parameter
Score test
(p value) for
any-cancer
model
Score test
(p value) for
definition-2
cancer model
Score test
(p value)
for definition-1
cancer model
†ADC (x10-3 mm2s-1) 7.95 (0.005*) 7.08 (0.008*) 6.74 (0.009*)
†T2-nSI 7.34 (0.007*) 12.3 (<0.001*) 11.0 (0.001*)
†DCE-nSI 1.32 (0.250) 2.47 (0.116) 1.65 (0.199)
SoE 0.66 (0.417) 0.17 (0.678) 0.55 (0.459)
ME 12.9 (<0.001*) 9.46 (0.002*) 8.79 (0.003)
*Etype 0.38 (0.144) 0.39 (0.532) 0.14 (0.711)
AUCtot 4.77 (0.029*) 2.51 (0.113) 3.23 (0.720)
Definition-2 cancer defined as≥Gleason 3+4 or a template biopsy cancer
core length of≥4 mm. Definition-1 cancer defined as≥Gleason 4+3 or a
template biopsy cancer core length of≥6 mm
ADC – apparent diffusion coefficient; T2-nSI – normalized T2 signal
intensity, DCE-nSI – normalized early arterial enhanced T1 signal inten-
sity, SoE – slope of enhancement, ME –maximum enhancement, Etype –
curve shape type, AUCtot – area under enhancement curve, ROC –
receiver operating characteristic, AUC – area under curve
* Significant contribution to model
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Twenty of 85 patients within the temporal validation group
were classified as equivocal for significant tumours by radiol-
ogist A (Pi-RADS score 3); 8/20 were subclassified as 3+ and
12/20 as 3-. Within this group, there were seven (35 %)
definition-2 cancers and 13 (65%) benign/insignificant cancers.
The sensitivity and specificity of the radiologist A subclassifi-
cation for significant cancer were 0.14 and 0.54, respectively
(c.f. LR model sensitivity of 0.71 and specificity of 0.61).
The ROC-AUC for radiologist B was 0.74 (95 % CI 0.63–
0.86). The sensitivity/specificity of radiologist B for cancer
was 0.88/0.47, 0.95/0.37 and 0.92/0.32 using a score≥3 as
positive; and 0.42/0.92, 0.54/0.85 and 0.64/0.81 using≥4 as
positive for any-cancer, definition-2 and definition-1 cancer,
respectively.
Thirty-nine of 85 patients within the temporal validation
group were classified as equivocal for significant tumour by
radiologist B (Pi-RADS score 3); 14/39 were sub-classified as
3+ and 25/39 as 3-. Within this group, there were ten (26 %)
definition-2 cancers and 29 (74%) benign/insignificant cancers.
The sensitivity and specificity of radiologist B sub-
classification for significant cancer were 0.40 and 0.34, respec-
tively (c.f. LRmodel sensitivity of 0.50 and specificity of 0.76).
Discussion
Summary of results
There are two reasons why a radiologist may miss a cancer:
(1) the radiologist saw the cancer, but dismissed it as benign
change; or (2) the radiologist did not see the cancer. In this
Fig. 5 (a) Receiver operating characteristic curves for temporal valida-
tion of CAD models to classify the presence of any-cancer [green],
definition-2 cancer (≥4 mm with ≥ Gleason 3+4) [yellow], and defini-
tion-1 cancer (≥6 mm with ≥ Gleason 4+3) [red]. Corresponding area-
under-curve of 0.76 (95 % CI 0.66–0.87), 0.67 (95 % CI 0.55–0.79) and
0.70 (95 % CI 0.55–0.85) (b) Receiver operating characteristic curve of
radiologist A (black line) and radiologist B (dashed black line) Pi-RADS
score for classification of clinically significant transition zone cancer; area
under curve of 0.65 (95 % CI 0.51–0.79) and 0.74 (95 % CI 0.63–0.86),
respectively. The red line demonstrates the ROC curve for the logistic
regression model
Table 3 Radiologists Pi-RADS
score for the temporal validation
cohort (n=85)
Pi-RADS score for the presence of
significant disease within the se-
lected ROI (1=significant tumour
highly unlikely, 2=significant tu-
mour unlikely, 3=equivocal, 4=
significant tumour likely, 5=sig-
nificant tumour highly likely).
ROI – region of interest
*≥Gleason 3+4 or a template bi-
opsy CCL of≥4 mm
† ≥Gleason 4+3 or a template bi-
opsy CCL of≥6 mm
Radiologist
Pi-RADS
Score
Total number
of ROIs
ROIs positive
for *definition-2
cancer
ROIs negative
for *definition-2
cancer
ROIs positive
for any-cancer
ROIs positive
for †definition-1
cancer
Radiologist A
1 0 0 0 0 0
2 56 12 44 25 5
3 20 7 13 12 4
4 6 3 3 6 3
5 3 3 0 3 2
Radiologist B
1 0 0 0 0 0
2 24 2 22 6 1
3 39 10 29 21 4
4 16 9 7 13 5
5 6 4 2 6 4
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study, we assessed whether a mp-MRI derived LR model
could address the former problem; i.e., whether it has the
potential to aid the radiologist in making classification deci-
sions. Whilst overall we found that our LR model was as
accurate as an experienced radiologist at determining whether
an area was clinically significant prostate cancer or a benign
change, ROC-AUC 0.65 (radiologist A), 0.74 (radiologist B)
versus 0.67 (LR model); for Pi-RADS score=3 (equivocal)
areas, our LR model outperformed radiologists’ “best guess”.
Comparison with existing work
The three variables that proved to be the best classifiers in our
LR models were: ADC, T2nSI and ME. In turn, these relate
to: tissue cellularity; water content and tissue vascularity [26].
Others have used similar inputs into their models, but mainly
where applied to peripheral zone tumours. For example, Lang-
er et al. [3] found ADC, T2 and Ktrans were the best classifiers
within the peripheral zone, whilst Shah et al. [27] report
performance of ADC>DCE> normalized T2 weighted
imaging for classification of peripheral zone tumour. In
line with peripheral zone classification, we confirm that
ADC is also of primary importance for classifying transition
zone tumours.
Our results show that the principal problem faced by the
radiologist when assessing the transition zone is a reduction in
sensitivity for diagnosis of clinically significant disease. This
concurs with the findings of others [28, 29].
In agreement with other findings [29, 15], we found no
overall benefit of using mp-MRI LR versus T2-only LR
models when applied to all patients. However, when specifi-
cally applied to lesions classified by radiologists as Pi-RADS
3 (equivocal), the mp-MRI LR model was a better classifier
than the T2-only LR model.
Similar to our work, a recent publication also tested a mp-
MRI TZ-specific diagnostic model [15]. Their results show a
higher ROC-AUC of 0.87 (95 % CI 0.78, 0.96) for the
depiction of TZ prostate cancer when compared with our
work. This, however, is likely to be explained by differences
in study population and histological reference standard, where
we use a lower threshold for significant tumour and smaller
tumours within our patient cohort. By way of explanation, the
median volume of TZ prostate cancer in the study by
Hambrock et al. [15] was 2.5 ml (range, 0.5–12.48 ml). In
addition, Hambrock et al. defined significant tumour based on
a threshold volume of 0.5 ml (approximately equivalent to a 1-
cm diameter lesion), irrespective of Gleason grade. In com-
parison, our median volume of TZ prostate cancer was signif-
icantly lower at 0.8 ml (range, 0.2–1.2 ml) and significant
tumour was defined either by volume (>0.2 ml; equivalent to a
CCL of 4 mm [19]), or any size tumour that includes Gleason
primary or secondary pattern 4.
Methodological limitations
Our study has some potential limitations. Firstly, we did not
have access to radical prostatectomy specimens as ground-
truth. However, we believe that our employment of a TPM-
based reference standard [30] helps to avoid spectrum bias
that can occur with studies based on prostatectomy specimens.
Secondly, TPM is a significant improvement over a TRUS
biopsy reference standard [19, 31] used by others. We ac-
knowledge that theremay still be some error inmatching TPM
histopathology with mp-MRI. However, it should be noted
that prostatectomy specimens themselves are not free from
artefacts due to processing (shrinkage, distortion, tissue-loss),
which also impair accurate co-registration with imaging [32].
Furthermore, we aimed to reduce misregistration error by
limiting the number of divisions of the transition zone (four
sectors), basing divisions on easily identifiable landmarks and
employing consensus for experienced radiologists’ opinions
on ascribing the location of ROIs. Indeed, we believe that
misregistration error has not impeded our LR model
performance.
For our MRI protocol, we followed the recommendations
from the European Consensus meeting [1], which suggests
that imaging could be adequately performed at a 1.5 T (such as
the one used in this work), but we acknowledge that a 3 TMRI
protocol may have improved performance of both our radiol-
ogists and the derived LR models.
Whilst recommended by other studies [33], we did not use
endorectal coils, and we note that the European Consensus
Meeting failed to reach agreement on their necessity even at
1.5 T [1]. In our experience, the use of endorectal coils has not
proven to be a significant detriment to overall performance of
mp-MRI at 1.5 T [34]. Our previous work and that of others
who have not employed endorectal coils and imaged at 1.5 T
has shown comparable performance of mp-MRI with those
studies that image with endorectal coils [17, 35–37]. Howev-
er, the performance of our LR model in data sets generated at
3 T and with use of endorectal coils remains to be established.
Finally, whilst we have derived and tested LR models, the
next step remains to integrate these models into a CAD
package and test radiologist performance with and without
CAD.
Clinical implications
Radiologists tend to use an ordinary scale of 1 to 5 when
attributing the likelihood of clinically significant cancer to the
whole prostate or to a given sector within [1]. These scores
only have clinical utility if they assist in a management deci-
sion. When a radiologist scores a 4 or 5, he/she expects that a
biopsy will be triggered for that sector. In contrast, a patient
who is attributed a score of 1 to 2 may indeed avoid a biopsy
[10, 38–40]. However, patients scored as 3 remain a
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heterogeneous group, with some undergoing biopsy whilst
others often opt for active surveillance. We therefore assessed
if the LR model could help specifically classify patients clas-
sified as Pi-RADS 3.
Indeed, the sensitivity/specificity of the LR model within
this group was higher than both of our radiologists’ “best-
guesses”; suggesting that the LR model could have utility as a
‘second opinion’ when radiologists are unsure about a transi-
tion zone region.
The next step is the integration of the LRmodel into a CAD
package that generates probability maps. Future work will
assess whether the CAD package indeed improves a radiolo-
gist’s performance, as suggested by our results.
Conclusions
We demonstrate that overall performance of transition zone
specific mp-MRI LR model is similar to an experienced
radiologist, and moreover that the LR model improves classi-
fication of Pi-RADS score 3 lesions located within the transi-
tion zone.
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